{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"2.6"}]}],"title":"Day 1 to ≤ Day 28"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6"},{"groupId":"OG001","value":"5.4"}]}],"title":"Day 29 to ≤ Day 56"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0"},{"groupId":"OG001","value":"8.5"}]}],"title":"Day 57 to ≤ Day 84"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3"},{"groupId":"OG001","value":"10.3"}]}],"title":"Day 85 to ≤ Day 112"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7"},{"groupId":"OG001","value":"12.4"}]}],"title":"Day 113 to ≤ Day 140"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2"},{"groupId":"OG001","value":"16.8"}]}],"title":"Day 141 to ≤ Day 168"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1"},{"groupId":"OG001","value":"15.9"}]}],"title":"Day 169 to ≤ Day 179"}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"158"}],"units":"Participants"}],"description":"All corticosteroid dosages prescribed to the participant and all dose changes during the study were to be recorded for assessment of participants who successfully tapered off of all corticosteroids. Participants who completely tapered off corticosteroids refer to those who permanently discontinued steroids as per the dose administration panel and who did not restart steroids in the same interval. Participants who were tapered off and continued follow-up were also counted as being tapered off with 0 dose in subsequent intervals until they discontinued from the main treatment period or restarted steroid treatment.","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"},{"description":"Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.","id":"OG001","title":"Best Available Therapy"}],"paramType":"NUMBER","populationDescription":"FAS. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"up to Day 179","title":"Percentage of Participants Successfully Tapered Off of All Corticosteroids","type":"SECONDARY","unitOfMeasure":"percentage of participants"}